Bevespi Aerosphere (glycopyrrolate/ formoterol fumarate) Inhalation Aerosol

Bronchodilators are used to prevent and treat chronic obstructive pulmonary disease (COPD). Bronchodilators work by relaxing the muscles in the airways (bronchi), making the airways widen and allowing more air to travel in and out of the lungs.1

What is Bevespi Aerosphere?

Bevespi Aerosphere (glycopyrrolate 9 mcg/formoterol fumarate 4.8 mcg) is an inhalation aerosol used for the long-term, maintenance treatment of airflow obstruction in people with COPD. Bevespi Aerosphere should not be used for the relief of acute bronchospasm or for the treatment of asthma.2

What are the ingredients in Bevespi Aerosphere?

Active ingredients: micronized glycopyrrolate and micronized formoterol fumarate.

How does Bevespi Aerosphere work?

There are two medications that are combined in Bevespi Aerosphere:

  • Glycopyrrolate is a long-acting antimuscarinic agent (LAMA), which is often referred to as an anticholinergic. Antimuscarinic agents relax smooth muscle, and glycopyrrolate helps relax the smooth muscles that lead to the dilation of the bronchi. This action makes breathing easier.
  • Formoterol fumarate is a long-acting, selective beta2-adrenergic agonist (beta2-agonist) with a rapid onset of action. It also acts as a bronchodilator, relaxing the smooth muscle in the airways. Formoterol fumarate may also be called a long-acting bronchodilator, or LABA.2

What are the possible side effects of Bevespi Aerosphere?

Like all medications, Bevespi Aerosphere may cause unwanted side effects. The most common side effects experienced by patients taking Bevespi Aerosphere include urinary tract infection (UTI) and cough. Rarely, Bevespi Aerosphere can cause serious side effects, including sudden breathing problems immediately after inhaling the dose, serious allergic reactions (such as rash, hives, breathing problems, or swelling of the face, mouth, or tongue), increased blood pressure, chest pain, a fast or irregular heartbeat, tremor, nervousness, new or worsened eye problems, new or worsened urinary retention, high blood sugar, or low blood potassium.

People taking Bevespi Aerosphere should talk to their doctor about any side effects they are experiencing. People who experience severe side effects such as difficulty breathing or a serious allergic reaction should seek immediate medical attention.2

Things to know about Bevespi Aerosphere

Bevespi Aerosphere should not be used for the treatment of asthma. Long-acting beta(2)-adrenergic agonists (LABAs), such as formoterol fumarate, increase the risk of asthma-related death.

People who have a known allergy to glycopyrrolate, formoterol fumarate, or to any of the ingredients in Bevespi Aerosphere should not take this product.

Bevespi Aerosphere should not be used in combination with another LABA medicine or an anticholinergic because of the risk of overdose.

Bevespi Aerosphere should not be used for acute symptoms of COPD or in acutely worsening COPD. People taking Bevespi Aerosphere should have a rescue inhaler for sudden symptoms.
People should not use Bevespi Aerosphere more than prescribed (usually two inhalations twice daily).

People who have heart problems, high blood pressure, seizures, thyroid problems, diabetes, liver problems, glaucoma, prostate or bladder problems, or problems passing urine should talk to their doctor about their condition(s) before taking Bevespi Aerosphere.2

Dosing

The Bevespi Aerosphere inhaler provides a pressurized, metered dose containing a combination of glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg). Two inhalations equal one dose, and people with COPD should use 2 inhalations of Bevespi Aerosphere twice daily, in the morning and in the evening, talk to your doctor about your specific dosage.2

For additional information on Bevespi Aerosphere, read the full prescribing information here.

Written by: Anna Nicholson | Last reviewed: July 2015.
View References
  1. American Thoracic Society. Accessed online on 5/2/17 at https://www.thoracic.org/patients/patient-resources/resources/copd-medicines.pdf
  2. Bevespi Aerosphere prescribing information. Accessed online on 5/2/17 at https://www.azpicentral.com/bevespi/bevespi_pi.pdf.